IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade-Reference-Cited by-同舟云学术

IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

Published:2017-06-26 Issue:8 Volume:127 Page:2930-2940
ISSN:0021-9738
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:

Author:

Ayers Mark,Lunceford Jared,Nebozhyn Michael,Murphy Erin,Loboda Andrey,Kaufman David R.,Albright Andrew,Cheng Jonathan D.,Kang S. Peter,Shankaran Veena,Piha-Paul Sarina A.,Yearley Jennifer,Seiwert Tanguy Y.,Ribas Antoni,McClanahan Terrill K.

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Link

https://www.jci.org/articles/view/91190/files/pdf

Reference30 articles.

1. The blockade of immune checkpoints in cancer immunotherapy

2. Oncology Meets Immunology: The Cancer-Immunity Cycle

3. PD-1 and Its Ligands in Tolerance and Immunity

4. PD-1 blockade induces responses by inhibiting adaptive immune resistance

5. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection

Cited by 2668 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inflammatory response signature score model for predicting immunotherapy response and pan-cancer prognosis;Computational and Structural Biotechnology Journal;2024-12

2. Mime: A flexible machine-learning framework to construct and visualize models for clinical characteristics prediction and feature selection;Computational and Structural Biotechnology Journal;2024-12

3. Powerful microscopy technologies decode spatially organized cellular networks that drive response to immunotherapy in humans;Current Opinion in Immunology;2024-12

4. Tumor immune microenvironmental characteristics in Human Epidermal Growth Factor-2 (HER2) positive esophageal adenocarcinoma: A comparative analysis and biomarker study;Translational Oncology;2024-11

5. Alterations in intratumoral and peripheral immune status in recurrent gliomas and their prognostic implications for patients underwent reoperation;International Immunopharmacology;2024-10